“…Although little more than 20 years has passed since the first human embryonic stem cells (ESC) were reported (Thomson et al, 1998, Reubinoff et al, 2000, and less than 14 years since human induced pluripotent cells (iPSC) were described (Takahashi et al, 2007, Yu et al, 2007, clinical trials for regenerative medicine using derivatives of these cells are already underway or on the horizon (da Cruz et al, 2018, Schwartz et al, 2012, Song et al, 2015, Mandai et al, 2017, Barker et al, 2017). Yet over this period it has become evident that both human ESC and iPSC (collectively here denoted as PSC), although mostly diploid when first derived, may acquire genetic alterations, ranging from large scale structural modifications readily recognized as karyotypic variants through to single base pair changes on subsequent passage (Figure 1).…”